EDITOR'S PAGE CHEMICAL & ENGINEERING NEWS 1155-16th St., N.W., Washington, DC 20036 (202) 872-4600; TDD (202) 872-6355 EDITOR-IN-CHIEF: Rudy M. Baum MANAGING EDITOR: Pamela S. Zurer ART DIRECTOR: Robin L. Braverman, Nathan Becker (Associate Art Director) Linda Mattingly (Staff Artist) SENIOR CORRESPONDENT: Lois R. Ember NEWS EDITOR: William G. Schulz EDITOR-AT-LARGE: Michael Heylin CONTRIBUTING EDITORS: Susan J. Ainsworth, K. M. Reese SENIOR ADMINISTRATIVE OFFICER: Lisa Dimaio lekel
ADMINISTRATIVE ASSISTANT: Patricia Oates BUSINESS Michael McCoy, Assistant Managing Editor NORTHEAST: (732) 906-8300. Rick Mullin (Senior Editor), Marc S. Reisch (Senior Correspondent), William J. Storck (Senior Correspondent), Alexander H. Tullo (Associate Editor), Rachel Eskenazi (Administrative Assistant). HONG KONG: 852 2984 9072. Jean-Francois Tremblay (Bureau Head). LONDON: 44 20 8870 6884. Patricia L. Short (Senior Correspondent) GOVERNMENT & POLICY David J. Hanson, Assistant Managing Editor WASHINGTON: (202) 872-4495. Bette Hileman (Senior Editor), Cheryl Hogue (Senior Editor), Jeffrey W. Johnson (Senior Editor), Susan R. Morrissey (Associate Editor) SCIENCE/TECHNOLOGY/EDUCATION Doron Dagani, Assistant Managing Editor WASHINGTON: (202) 872-4411. Stuart A. Borman (Senior Correspondent), Louisa W. Dalton (Assistant Editor), Bethany Halford (Assistant Editor). Celia M. Henry (Associate Editor), Stephen K. Ritter (Senior Editor), A. Maureen Rouhi (Senior Correspondent), Sophie L. Rovner (Senior Editor), Amanda T. Yarnelt (Associate Editor). CHICAGO: (847) 679-1156. Mitch Jacoby (Senior Editor). WEST COAST: (510) 849-0575. Elizabeth K. Wilson (Senior Editor). LONDON: 44 1256 811052. Michael Freemantle (Senior Correspondent) ACS NEWS & SPECIAL FEATURES Linda Raber, Head Victoria M. Gilman (Editorial Assistant). Corinne A. Marasco (Associate Editor), Aalok Mehta (Assistant Editor) EDITING & PRODUCTION Robin M. Giroux, Assistant Managing Editor Melissa A. Braddock (Editorial Assistant), Janet S. Dodd (Senior Editor), Arlene Goldberg-Gist (Senior Editor). Deanna Miller (Associate Editor). Stephen M. Trzaska (Associate Editor), Linda Wang (Assistant Editor) C&EN ONLINE Melody Voith, Editor Luis A. Carrillo (Production Manager), Wes M. Lindamood (Production Associate), Rachel Sheremeta Pepling (Assistant Editor), Nick Wafle (Manager, Chemjobs) PRODUCTION & IMAGING Vincent L. Parker (Assistant Director) Krystal E. King (Senior Digital Production Associate) SALES & MARKETING Elise Swinehart, Manager ADVISORY BOARD Paul S. Anderson. Shenda M. Baker, Donna G. Blackmond, Ronald Breslow. Stephanie A. Burns, Cynthia J. Burrows, Alison Butler, Margaret A. Cavanaugh, Sibrina N. Collins, Terry Collins, homas M. Connelly Jr., Thomas E. D'Ambra, Nance K. Dicciani. Richard M. Gross. Rudolf Hanko, Nancy B. Jackson, Carl A. Jennings, Fran Keeth, Robert L. Lichter, Jonathan MacQuitty, Peter Nagler, George A. Olah, Lura J. Powell, Douglas J. Raber. Geraldine L. Richmond, Gregory H. Robinson, Michael E. Rogers, Jeremy Scudamore, Jay M. Short, Ian Shott, Jay S. Siegel, Sergey A. Vasnetsov, John T. Yates Published by the AMERICAN CHEMICAL SOCIETY Madeleine Jacobs, Executive Director Robert D. Bovenschulte, President. Publications Division EDITORIAL BOARD Theodore L. Brown (Chair), ACS Board of Directors Chair: James D. Burke, ACS President: Charles P. Casey, Ned D. Heindel, Peter C. Jurs, Elsa Reichmanis, Peter J. Stang Copyright 2004, American Chemical Society Canadian GST Reg. No. R127571347
No Safety Net
T
HIS WEEK'S ISSUE OF C&EN CONTAINS
our annual special report on custom chemicals. The four stories that compose the feature paint a picture of an important segment of the chemical industry that is being buffeted by pricing pressures from its pharmaceutical industry customers, significant overcapacity, and fierce competition, among both the traditional players and new ones that are springing up, especially in Asia. The special report was written by Senior Correspondent A. Maureen Rouhi, who has been covering custom and fine chemicals for C&EN for the past three years. 'All four stories elaborate on the same message," Rouhi says. "Commercial custom chemicals manufacturers are caught between a rock and a hard place. Short term, the fundamentals of the business are unfavorable. Longer term, the challenges may be more formidable: How to offer a unique selling proposition, and what to do about competition from India and China. This last problem, I think, is the most worrisome, because the barriers to outsourcing are steadily crumbling." In the overview story that begins on page 25, Rouhi makes clear the extent of the overcapacity problem. Of the 79,000 m 3 of total capacity owned by pharmaceutical companies and custom chemicals manufacturers in 2002, fully 37% was idle. Because drug companies are launching fewer new chemical entities, custom manufacturers are turning their attention to producing active pharmaceutical ingredients for generic drugs. But generics are no panacea. Manufacturing generic APIs is a fundamentally different business than exclusive synthesis, Rouhi points out, often involving complex patent issues and touchy relations with brand-name drug companies. If you want a quick sketch of the pressures customers are placing on custom manufacturers, just take a look at the box on page 36. Before 2000, many features of custom manufacturing contracts wove together a sturdy safety net for the custom suppliers. No more. Contracts are for much shorter times, numerous companies are invited to bid, and most of the risks have been shifted to the suppliers. Despite all that, "The good news is that supplying the pharmaceutical industry is
fundamentally a sound business," Rouhi writes. "Drug companies still provide one of the highest returns on investment, and they can be expected to outsource chemistry, manufacturing, and other activities to further improve their financial positions." But the fact that it is a sound business means that other, lower cost competitors are being attracted to custom manufacturing. 'As Asian manufacturers pile on quality, credibility and reliability over their unbeatable cost structure, some observers predict that pharmaceutical custom manufacturing... will move to Asia," Rouhi writes. C&EN has already written about the increasing globalization of R & D functions, most recently in an article on drug discovery R&D shifting to India, China, and Russia by Assistant Managing Editor for Business Michael McCoy and Hong Kong Bureau Head JeanFrancois Tremblay (Dec. 1,2003, page 15). McCoy and Tremblay point out that drug discovery companies in these countries "are enjoying a stunning rise." McCoy and Tremblay write: "The U.S. economy has historically generated wealth by concentrating on activities with high economic value. R&D, particularly in the pharmaceutical area, is precisely one of these activities, and it's unclear how the U.S. can remain prosperous if R&D follows manufacturing on the trek to low-cost locations abroad." The effects of globalization on the chemical enterprise, including the impact on chemical employment in the U.S., is a topic I intend to return to occasionally on this page. Globalization is often portrayed as an inexorable force, the effects of which we simply have to adapt to. I agree that globalization is a powerful force, and that its effects are often, on balance, positive. But globalization appears also to have the potential to shred the employment safety net that many chemical professionals believed their education and skills had created for them. I invite readers to share with me their thoughts on and their experiences with a globalizing chemical enterprise. Thanks for reading.
Editor-in-chief
Views expressed on this page are those of the authi HTTP://WWW.CEN-ONLINE.ORG
C&EN/
JANUARY
19,2004
5
